JavaScript is currently not supported/disabled by this browser. Please enable JavaScript for full functionality.

Call Us 1 - 866 - 986 - 9598
[email protected]

Sign Up

Login
- My Order
- Return Requests
- Track my Order

Home / Cells / Cell Lines

CD38 CHO Recombinant Cell Line (Low Expression)

SKU : BHC18200307

Contact us to order

Tel

+1 866.986.9598

Email

[email protected]

Get a Quote

Request More Infos

BPS Bioscience

view supplier details

Order Now

Credit card payments now incur a 3% fee.

Contact us to order

Tel

+1 866.986.9598

Email

[email protected]

Get a Quote

Ask Merchant

Request More Infos

Sample Request

Mfr.No.	79615-L
Description	Recombinant clonal stable CHO cell line constitutively expressing full length human CD20 protein, also known as MS4A1 (Genbank #NM_152866). Surface expression of CD20 was confirmed by flow cytometry. Each stable clonal cell line was selected for different levels of CD20 [removed]High, Medium) to mimic different stages of cancer target cells with various CD20 expression levels. Mycoplasma testing: This cell line has been screened using the MycoAlert Mycoplasma Detection Kit (Lonza, #LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set (Lonza, #LT07-518) was used as a positive control. Host Species: hamster Supplied as Each vial contains ~ 2 x 10^6 cells in 1 ml of 10% DMSO in FBS.
Background	CD38 (cyclic ADP-ribose hydrolase 1, ADPRC1) is a glycoprotein and ectoenzyme which plays an important role in regulating intracellular calcium. CD38 is a highly attractive target antigen for immunotherapy because it is highly expressed on multiple myeloma cells, and at relatively low levels on normal lymphoid and myeloid cells. Expression of CD38 has also been associated with HIV infection, leukemia, and type II diabetes mellitus. CD38 CAR-T is a T cell product engineered by retroviral transduction to express a fully human CD38-specific CAR (chimeric antigen receptor). In 2015, the FDA approved daratumumab (Darzalex), a breakthrough therapy drug targeting CD38, for the treatment of multiple myeloma.
Application	Useful as CD38-expressing target cells in co-culture assays with CD38 CAR-T cells, for both CD38-specific cell killing assay and cytokine production assay.
Host Cell	CHO
Uniprot	P28907
Species	Human
Synonyms	cluster of differentiation 38, cyclic ADP ribose hydrolase
Shipping Temperature	-80°C (dry ice)
Note	LICENSE DISCLOSURE: Purchase of this cell line grants you with a 10-year license to use this cell line in your immediate laboratory, for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make the cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit the use of this cell line in humans or for therapeutic or drug use. The license does not permit modification of the cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license and result in an immediate cease of sales and distribution of Biohippo products to your laboratory. Biohippo does not warrant the suitability of the cell line for any particular use, and does not accept any liability in connection with the handling or use of the cell line. Modifications of this cell line, transfer to another facility, or commercial use of the cells may require a separate license and additional fees; contact [email protected] for details. Publications using this cell line should reference Biohippo Inc. Warning: Avoid freeze/thaw cycles.

Storage Stability	Store in liquid nitrogen immediately upon receipt.

Reference	1. van de Donk, NW, et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunological Reviews. 2016 Mar; 270: 95-1122. Drent, E, et al. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered against T cells for the treatment of multiple myeloma. Haematologica. 2016 May; 101 (5): 616-6253. Sanchez, L, et al. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. Journal of Hematology & Oncology. 2016 Jun; 9: 51

Product Manual	Datasheet

Have you used this product?

Rate it now..!!

Login to Review

SKU	Supplier No.	Size	Your price	Quantity
BHC18200307	79615-L	2 vials	$7865		Add to Cart

ebiohippo.com provides biomedical researchers with a one-stop informatic shopping experience by transforming biotechnology products’ data into a ready-to-analyze state. We collect and unify suppliers’ data on a single platform to reduce the time of searching, uncertainty, and cost of scientific experiments.

© 2024 Biohippo. All rights reserved.